Nigella sativa for the treatment of COVID‐19 patients: A rapid systematic review and meta‐analysis of randomized controlled trials

Abstract

Abstract Nigella sativa is an herbal therapy for various afflictions. It has some potential to be a promising option as an efficacious treatment for COVID‐19 patients that can contribute to global healthcare as a relatively cheap therapy but evidence of its use from randomized controlled trials (RCTs) is limited. Therefore, to explore the effect of N. sativa in combating COVID‐19, we undertook this meta‐analysis. We searched several databases to retrieve all RCTs investigating N. sativa for the treatment of COVID‐19 as compared to placebo or standard care. We used RevMan 5.4 for all analyses with risk ratio (RR) or odds ratio (OR) as the effect measures. We included a total of seven RCTs in this review. N. sativa significantly reduced the risk of all‐cause mortality in patients with COVID‐19 compared to the control group (RR 0.27, 95% CI: 0.10 to 0.72; I2 = 0%). N. sativa significantly reduced the rate of viral PCR positivity (RR 0.62, 95% CI: 0.39 to 0.97; I2 = 0%). We did not find any significant difference in the risk of hospitalization (RR 0.26, 95% CI: 0.04 to 1.54; I2 = 0%) and the rate of no recovery (OR 0.48, 95% CI: 0.20 to 1.15; I2 = 84%) between the two groups. N. sativa is an easily available herbal medicine that may decrease the risk of mortality and improve virological clearance in COVID‐19 patients. However, our results are limited by the small number of RCTs available. Further large‐scale RCTs are needed to better understand the anti‐inflammatory and antiviral effects of N. sativa in COVID‐19 patients.

Keywords

• COVID‐19
• cumin
• meta‐analysis
• Nigella sativa
• SARS‐CoV‐2